Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

This study is currently recruiting participants.
Verified June 2013 by Stanford University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Samuel Strober, Stanford University
ClinicalTrials.gov Identifier:
NCT00319657
First received: April 28, 2006
Last updated: June 26, 2013
Last verified: June 2013
  Purpose

The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone Marrow Transplantation are enrolling patients into a research study to determine if blood stem cells injected after kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn. Patients must have a healthy, completely human leukocyte antigen (HLA)-matched brother or sister as the organ and stem cell donor.

One to two months before kidney transplant surgery, blood stem cells will be removed from the donor and the cells will be frozen. After transplant surgery, the recipient will receive radiation and anti-T cell antibody treatments for two weeks to prepare for injection of the stem cells. The stem cells will be injected at the end of the two-week treatment. If the stem cells persist in the recipient, immunosuppressive drugs will be gradually reduced until they are withdrawn completely at least six months after transplantation. Patients will be followed in the Stanford clinics for transplant patients. Patients who live outside of the San Francisco Bay Area must remain near Stanford for six weeks after transplant surgery.


Condition Intervention Phase
Immune Tolerance
Device: Immune tolerance
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Discontinuation of maintenance immunosuppressive drugs [ Time Frame: Measured at 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: July 2004
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Immune tolerance, kidney transplantation
Induction of immune tolerance in HLA-matched living donor kidney transplantation
Device: Immune tolerance

Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for at least 6 months. Immunosuppressive drugs are stopped at 6 to 12 months if stable mixed chimerism achieved and there is no rejection of the transplant kidney.

The IDE used in this study is the column used for hematopoietic cell sorting.


Detailed Description:

The purpose of this study is to determine the proportion of patients that can be withdrawn completely from immunosuppressive drugs while maintaining normal function of HLA-matched living related donor kidney transplants. Fifteen participants will be conditioned with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (ATG), and given an infusion of donor "mobilized" blood mononuclear cells prior to transplantation.

This is a single-center, open-label study in adult renal transplant patients. Fifteen patients will receive TLI, ATG, and an infusion of CD34+ selected G-CSF mobilized blood cells combined with a fixed number (1x10^6) of CD3+ T cells from the same mobilized blood cell source. Patients will receive a one-month course of mycophenolate mofetil and a six-month tapering course of cyclosporine that will be discontinued at six months. At serial timepoints (1) graft function will be monitored, (2) chimerism will be measured in recipient white blood cell subsets, (3) mixed lymphocyte response (MLR) assays of peripheral blood mononuclear cells against donor and third party cells will be performed, and (4) protocol biopsies of the graft will be obtained. An attempt will be made to discontinue cyclosporine at six months if (1) chimerism is detectable for at least 180 days after CD34+ and CD3+ cell infusion, (2) there is stable graft function without clinical rejection episodes, and (3) there is lack of histologic rejection on protocol biopsies. In the proposed study, patients will be given a target dose of 8-10x10^6 CD34+ cells/kg and 1x10^6 CD3+ cells/kg because sustained chimerism may be necessary for sustained tolerance to the graft.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Kidney transplant performed at Stanford University Medical Center
  • Have an HLA-matched sibling donor
  • No known contraindication to administration of rabbit ATG or radiation
  • Willing to use a reliable form of contraception for at least 24 months following transplantation

Exclusion Criteria:

  • Previous treatment with rabbit ATG or a known allergy to rabbit proteins
  • History of cancer, other than non-melanoma skin cancer
  • Pregnant or breastfeeding
  • HIV, Hepatitis B, or Hepatitis C infection
  • Previous organ transplant
  • Leukopenia (white blood cell count less than 3000/mm³)
  • Thrombocytopenia (platelet count less than 100,000/mm³)
  • Panel reactive antibody (PRA) level greater than 20%
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00319657

Contacts
Contact: Stephan Busque, MD 650-498-6189 sbusque@stanford.edu
Contact: Asha Shori, CCRP 650-736-0245 ashas@stanford.edu

Locations
United States, California
Stanford University, School of Medicine Recruiting
Stanford, California, United States, 94305
Principal Investigator: Samuel Strober, MD         
Sub-Investigator: Stephan Busque, MD         
Sub-Investigator: John Scandling, MD         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Samuel Strober, MD Stanford University
  More Information

Additional Information:
Publications:
Responsible Party: Samuel Strober, Chair of Study, Stanford University
ClinicalTrials.gov Identifier: NCT00319657     History of Changes
Other Study ID Numbers: 367, P01HL075462-02, P01 HL075462-02
Study First Received: April 28, 2006
Last Updated: June 26, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Stanford University:
Kidney Transplantation
Blood Stem Cell Transplantation

Additional relevant MeSH terms:
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014